Zacks Investment Research on MSN
Are GLP-1 drugs becoming a meaningful revenue driver for CAH stock?
Cardinal Health CAH is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more ...
Zacks Investment Research on MSN
Can specialty momentum push CAH's earnings growth beyond 25% in FY26?
Cardinal Health’s CAH accelerating specialty strategy is increasingly becoming the centerpiece of its earnings expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results